与人工智能交易:CoPilots,而非顾问

币界网2024-08-08 tarihinde yayınlandı2024-08-08 tarihinde güncellendi

币界网报道:

现在已经是八月了,这意味着金融巨头太平洋峰会(FMPS)的最后倒计时现在正式开始。亚太地区最大的活动将于8月27日至29日在澳大利亚悉尼举行,吸引业内精英以及数千名与会者、交易员等。

未来的与会者可以期待向专家演讲者、思想领袖和顶尖教育工作者学习,这是为期两天的澳大利亚及其他地区零售贸易行业庆祝活动的一部分。这包括一个拥挤的议程,其中包含大量针对零售交易人群量身定制的内容。

你对FMPS即将推出的产品感到好奇吗?前往网站查看今天的完整议程,并在日历上标记最重要的会议。首届活动将在两个专门的内容阶段,即中心阶段和交流区,举办小组讨论、研讨会、会议等。一场值得关注的会议将是即将举行的研讨会,“与人工智能交易:CoPilots,而不是Advisors”。

作为一个快速提醒,现在在线预订FMPS座位还不算太晚。时间不多了,所以一定要跳过今年8月在悉尼现场的排队,今天就注册参加亚太地区今年最大的活动!

为什么人工智能是一种工具,而不是答案

潜在的参与者可以在整个活动中利用大量的内容、社交机会和娱乐。然而,最大的吸引力之一将是充足的交易时段和对零售交易空间的重视,所有这些都可以在今年8月的交易区看到。

即将举行的“与人工智能交易:CoPilots,Not Advisors”会议可能是深入了解人工智能在交易中的作用以及如何最好地利用这一工具进行所有策略的最佳机会。

本次内容丰富的会议将于8月28日12:30-12:50在交流区举行。研讨会将由Traderflow创始人Anthony Darvall主持。与会者在本次会议上可以期待什么?

好吧,人工智能已经接管了编码和简单的任务,如总结和创建图片,这并不奇怪。在金融领域,人工智能的潜力是巨大的,因为交易者处理的信息量可能是压倒性的。交易副驾驶将根据交易者的交易习惯学习/观察/提醒他们,并及时提供风险管理和基本面/技术可操作信息。加入Darvall先生的行列,他希望简化交易流程,帮助交易者最大限度地减少屏幕时间。

Darvall先生在外汇市场拥有17年的丰富经验,曾任EasyMarkets.com的首席市场分析师。2022年,他从经纪业务转型为创立人工智能初创公司Traderflow。Traderflow旨在创建AI交易复制品,简化交易者的工作流程,减少对多个屏幕的需求,并将信息传输整合到一台笔记本电脑上。

这是今年八月你日历上要循环的一个环节。悉尼见!

İlgili Okumalar

Stock Price Doubles Within the Year, Plummets 20% After Resumption, Baolai Medical's 'Chip Backdoor Listing' Script Ends

On August 10, 2026, BPL (300246.SZ) resumed trading after a nearly week-long suspension and immediately fell by a 20% limit-down. This plunge was triggered by the termination of a planned controlling stake transfer, dashing earlier market speculation. In January 2026, Zhejiang Quwei Zhihe Partnership entered as a significant shareholder, sparking hopes. Investors speculated that its backer, Weigu Information—a specialized "little giant" company in high-reliability solid-state storage chips—might be seeking a backdoor listing through BPL. This "cross-industry restructuring" expectation fueled a strong rally, with BPL's stock price more than doubling in 2026 prior to the halt. However, the deal was called off on August 7, directly causing the sharp sell-off. Underlying BPL's vulnerability is its fundamentally weak business. The company, a medical device firm, is mired in losses, having reported three consecutive years of net losses totaling over 200 million yuan. Its core hemodialysis business is squeezed by government procurement price cuts, while growth in its patient monitor segment has stalled. Furthermore, BPL faces imminent debt pressure with convertible bonds worth approximately 218 million yuan due in September 2026, and its current stock price is far below the conversion price. The failed control transfer may represent a delayed release of negative news, but BPL's core challenges remain: reversing operational losses and addressing its urgent liquidity crisis.

marsbit2 saat önce

Stock Price Doubles Within the Year, Plummets 20% After Resumption, Baolai Medical's 'Chip Backdoor Listing' Script Ends

marsbit2 saat önce

İşlemler

Spot
活动图片